Nafiye Fulya İLHAN, Demet ÇİÇEK, İbrahim KÖKÇAM, Dilara TURGUT

The levels of serum chemokines in patients with Behçet's disease

Aim: As chemokines are involved in the regulation of immune responses and infl ammatory reactions, this study aimed to investigate the serum levels of some chemokines to determine whether they play roles in the pathogenesis of Behçet s disease (BD). Materials and methods: The study comprised 64 cases, allocated to active or inactive patient groups. The levels of serum macrophage inflammatory protein-1α (MIP-1α), epithelial neutrophil-activating protein-78 (ENA-78), and neutrophilactivating peptide-2 (NAP-2) were measured. Results: The serum levels of MIP-1α and ENA-78 were statistically higher in BD patients than controls (P = 0.032 and P = 0.023, respectively). However, NAP-2 levels did not differ significantly between patients and controls (P > 0.05). A significantly higher mean serum level of ENA-78 was found in patients with active disease compared to patients with inactive disease and controls (P = 0.029 and P = 0.003, respectively). However, mean serum MIP-1α and NAP-2 levels did not differ significantly between active and inactive patients (P > 0.05). Conclusion: In this study, there was a significant elevation of MIP-1α and ENA-78 supporting the role of neutrophil hyperactivity in BD. However, because chemokines insert their eff ects in the microenvironment and serum concentrations reflect a developing inflammatory process indirectly, we suggest that more comprehensive studies are needed to reveal the role of chemokines in the pathogenesis of the disease.

PDF

___

1. Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG. Etiopathogenesis of Beh çets disease with emphasis on the role of immunological aberrations. Clin Rheumatol 2010; 29: 1211- 6.
2. Tugal-Tutkun I. Behçet disease in the developing world. Int Ophthalmol Clin 2010; 50: 87-98.
3. Erkilic K, Evereklioglu C, Cekmen M, Ozkiris A, Duygulu F, Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçets disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003; 12: 107-16.
4. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behçets disease. Clin Exp Rheumatol 2001; 19: 19-24.
5. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th 1 polarization of the immune response in Behçets disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999; 42: 1967-74.
6. Dizdar O, Kalyoncu U, Karadag O, Akdogan A, Kiraz S, Ertenli I et al. Macrophage infl ammatory protein-1α: a link between innate immunity and familial Mediterranean fever? Cytokine 2007; 37: 92-5.
7. Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J Exp Med 1998; 187: 1-14.
8. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004; 36: 1882-6.
9. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991; 174: 1355-62.
10. Peveri P, Walz A, Dewald B, Baggiolini M. A novel neutrophilactivating factor produced by human mononuclear phagocytes. J Exp Med 1988; 167: 1547-59.
11. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophilactivating properties of the melanoma growth-stimulatory activity. J Exp Med 1990; 171: 1797-802.
12. Ozer HT, Erken E, Gunesacar R, Kara O. Serum RANTES, MIP-1α, and MCP-1 levels in Behçets disease. Rheumatol Int 2005; 25: 487-8.
13. International Study Group for Behçets Disease. Criteria for diagnosis of Behçets disease. Lancet 1990; 335: 1078-80.
14. Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, Işık N, Serdaroğlu P. Cytokines and chemokines in neuro-Behçets disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 2003; 145: 127-34.
15. Kim WU, Do JH, Park KS, Cho ML, Park SH, Cho CS et al. Enhanced production of macrophage inhibitory protein-1α in patients with Behçets disease. Scand J Rheumatol 2005; 34: 129-35.
16. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K. Macrophage inflammatory protein-1α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammator y neurological diseases. J Neurol Sci 1995; 129: 223-7.
17. Balkwill F. The molecular and cellular biology of the chemokines. J Viral Hepat 1998; 5: 1-14.
18. Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis ChC. Serum of patients with Behçets disease induces classical (proinfl ammatory) activation of human macrophages in vitro. Dermatology 2003; 206: 225-32.
19. Sugiyama K, Mukae H, Ishii H, Kakugawa T, Ishimoto H, Nakayama S et al. Elevated levels of interferon γ-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. Respirology 2006; 11: 708-14.
20. Olszyna DP, Opal SM, Prins JM, Horn DL, Speelman P, van Deventer SJ et al. Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-α, and epithelial cellderived neutrophil-activating protein-78 in urine of patients with urosepsis. J Infect Dis 2000; 182: 1731-7.
21. ZGraggen WA, Mazzucchelli L, Streiter RM, Mueller C. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 1997; 113: 808-16.
22. Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD. The β-thromboglobulins and platelet factor 4: blood plateletderived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol 2000; 67: 471-8.
23. Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A et al. Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vasc ular inflammation. J Am Coll Cardiol 2000; 48: 1591-9.
24. Walz A, Dewald B, von Tscharner V, Baggiolini M. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med 1989; 170: 1745-50.